Alternative splicing variant of vascular endothelial growth factor-A is a critical prognostic factor in non-small cell lung cancer

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1407-1413

  Matsuyama, Masahiro ^a   Chijiwa, Tsuyoshi ^a,f   Inoue, Yoshimasa ^c   Abe, Yoshiyuki ^b   Nishi, Masatake ^e   Miyazaki, Noriyuki ^a   Furukawa, Daisuke ^a   Mukai, Masaya ^c   Suemizu, Hiroshi ^d   Sekido, Yasutomo ^c   Ueyama, Yoshito ^c   Nakamura, Masato ^a,d  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Tokorozawa PET Diagnostic Imaging Clinic   (Japan)

^c TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^d CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^e Undersea Medical Center   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION DISASTER MEDICAL CENTER   (Japan)

Author keywords

Multivariate analysis; Non small cell lung cancer; Prognosis; VEGF189

Indexed keywords

CALVASCULIN; GELATINASE A; GELATINASE B; ISOPROTEIN; MESSENGER RNA; THROMBOSPONDIN 1; THROMBOSPONDIN 2; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN 189; VASCULOTROPIN A;

ADULT; AGE DISTRIBUTION; ALTERNATIVE RNA SPLICING; ARTICLE; CANCER GRADING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; VEIN DISEASE;

AGED; ALTERNATIVE SPLICING; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROGNOSIS; PROTEIN ISOFORMS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449350663     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000582     Document Type: Article

References (48)

1. Oshika Y, Masuda K, Tokunaga T, Hatanaka H, Kamiya T, Abe Y, Ozeki Y, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y and Nakamura M: Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clin Cancer Res 4: 1785-1788, 1998.
2. Nishi M, Abe Y, Tomii Y, Tsukamoto H, Kijima H, Yamazaki H, Ohnishi Y, Iwasaki M, Inoue H, Ueyama Y and Nakamura M: Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. Int J Oncol 26: 1517-1524, 2005.
3. Miyazaki N, Abe Y, Oida Y, Suemizu H, Nishi M, Yamazaki H, Iwasaki M, Inoue H, Ueyama Y and Nakamura M: Poor outcome of patients with pulmonary adenocarcinoma showing decreased E-cadherin combined with increased S100A4 expression. Int J Oncol 28: 1369-1374, 2006.
4. Chijiwa T, Abe Y, Inoue Y, Matsumoto H, Kawai K, Matsuyama M, Miyazaki N, Inoue H, Mukai M, Ueyama Y and Nakamura M: Cancerous, but not stromal, thrombospondin-2 contribute prognosis in pulmonary adenocarcinoma. Oncol Rep 22: 279-283, 2009.
5. Oshika Y, Nakamura M, Tokunaga T, Ozeki Y, Fukushima Y, Hatanaka H, Abe Y, Yamazaki H, Kijima H, Tamaoki N and Ueyama Y: Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol 12: 541-544, 1998.
6. Oshika Y, Nakamura M, Tokunaga T, Ohnishi Y, Abe Y, Tsuchida T, Tomii Y, Kijima H, Yamazaki H, Ozeki Y, Tamaoki N and Ueyama Y: Ribozyme approach to down-regulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC). Eur J Cancer 36: 2390-2396, 2000.
7. Abe Y, Ohnishi Y, Yoshimura M, Ota E, Ozeki Y, Oshika Y, Tokunaga T, Yamazaki H, Ueyema Y, Ogata T, Tamaoki N and Nakamura M: P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. Br J Cancer 74: 1929-1934, 1996.
8. Park JE, Keller GA and Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4: 1317-1326, 1993.
9. Ferrara N, Houck KA, Jakeman LB, Winer J and Leung DW: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 47: 211-218, 1991.
10. Houck KA, Ferrara N, Winer J, Cachianes G, Li B and Leung DW: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806-1814, 1991.
11. Veikkola T and Alitalo K: VEGFs, receptors and angiogenesis. Semin Cancer Biol 9: 211-220, 1999.
12. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
13. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, Keshet E and Neufeld G: VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 272: 7151-7158, 1997.
14. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N and Nakamura M: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77: 998-1002, 1998.
15. Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N and Nakamura M: Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 35: 133-137, 1999.
16. Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, Fukuda H, Nakano H, Abe S, Tateishi A, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y and Nakamura M: Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35: 1089-1093, 1999.
17. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA and Bouck NP: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87: 6624-6628, 1990.
18. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P and Detmar M: Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96: 14888-14893, 1999.
19. Kyriakides TR, Zhu YH, Yang Z and Bornstein P: The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice. J Histochem Cytochem 46: 1007-1015, 1998.
20. Lawler J: The functions of thrombospondin-1 and-2. Curr Opin Cell Biol 12: 634-640, 2000.
21. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ and Bouck N: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122: 497-511, 1993.
22. Kim MS, Kim YK, Cho KH and Chung JH: Infrared exposure induces an angiogenic switch in human skin that is partially mediated by heat. Br J Dermatol 155: 1131-1138, 2006.
23. Tokunaga T, Nakamura M, Oshika Y, Abe Y, Ozeki Y, Fukushima Y, Hatanaka H, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Tamaoki N and Ueyama Y: Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer 79: 354-359, 1999.
24. Werb Z, Vu TH, Rinkenberger JL and Coussens LM: Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 107: 11-18, 1999.
25. Kyriakides TR, Zhu YH, Yang Z, Huynh G and Bornstein P: Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 159: 1255-1262, 2001.
26. Oida Y, Yamazaki H, Tobita K, Mukai M, Ohtani Y, Miyazaki N, Abe Y, Imaizumi T, Makuuchi H, Ueyama Y and Nakamura M: Increased S100A4 expression combined with decreased E-cadherin expression predicts a poor outcome of patients with pancreatic cancer. Oncol Rep 16: 457-463, 2006.
27. Kamochi J, Tokunaga T, Tomii Y, Abe Y, Hatanaka H, Kijima H, Yamazaki H, Watanabe N, Matsuzaki S, Ueyama Y and Nakamura M: Overexpression of the thrombospondin 2 (TSP2) gene modulated by the matrix metalloproteinase family expression and production in human colon carcinoma cell line. Oncol Rep 10: 881-884, 2003.
28. Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251: 1451-1455, 1991.
29. Wheelock MJ and Jensen PJ: Regulation of keratinocyte intercellular junction organization and epidermal morphogenesis by E-cadherin. J Cell Biol 117: 415-425, 1992.
30. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D and Birchmeier W: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173-185, 1991.
31. Behrens J, Mareel MM, Van Roy FM and Birchmeier W: Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108: 2435-2447, 1989.
32. Schafer BW and Heizmann CW: The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 21: 134-140, 1996.
33. Takenaga K, Nakamura Y and Sakiyama S: Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells. Oncogene 14: 331-337, 1997.
34. Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Florenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ and Fodstad O: Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 56: 5490-5498, 1996.
35. The World Health Organization histological typing of lung tumours. Second edition. Am J Clin Pathol 77: 123-136, 1982.
36. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC and Lee YC: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19: 432-441, 2001.
37. Van Trappen PO, Ryan A, Carroll M, Lecoeur C, Goff L, Gyselman VG, Young BD, Lowe DG, Pepper MS, Shepherd JH and Jacobs IJ: A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer 87: 537-544, 2002.
38. Chijiwa T, Abe Y, Ikoma N, Yamazaki H, Tsukamoto H, Suemizu H, Kawai K, Wakui M, Nishime C, Matsumoto H, Matsuyama M, Mukai M, Ueyama Y and Nakamura M: Thrombospondin 2 inhibits metastasis of human malignant melanoma through microenvironment-modification in NOD/SCID/ gamma(c)(null) (NOG) mice. Int J Oncol 34: 5-13, 2009.
39. Kazuno M, Tokunaga T, Oshika Y, Tanaka Y, Tsugane R, Kijima H, Yamazaki H, Ueyama Y and Nakamura M: Thrombospondin-2 (TSP2) expression is inversely correlated with vascularity in glioma. Eur J Cancer 35: 502-506, 1999.
40. Nakamura M, Oida Y, Abe Y, Yamazaki H, Mukai, M, Matsuyama M, Chijiwa T, Matsumoto H and Ueyama Y: Thrombospondin-2 inhibits tumor cell invasion through the modulation of MMP-9 and uPA in pancreatic cancer cells. Mol Med Rep 1: 423-427, 2008.
41. Fontanini G, Boldrini L, Chine S, Pisaturo F, Basolo F, Calcinai A, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G: Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 79: 363-369, 1999.
42. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C and Brambilla E: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188: 369-377, 1999.
43. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K and Harris AL: Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82: 1427-1432, 2000.
44. Baillie R, Carlile J, Pendleton N and Schor AM: Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol 54: 116-120, 2001.
45. Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, Weyant RJ and Landreneau RJ: Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8: 72-79, 2001.
46. Stefanou D, Batistatou A, Arkoumani E, Ntzani E and Agnantis NJ: Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. Histol Histopathol 19: 37-42, 2004.
47. Tomii Y, Yamazaki H, Sawa N, Ohnishi Y, Kamochi J, Tokunaga T, Osamura Y, Sadahiro S, Kijima H, Abe Y, Ueyama Y, Tamaoki N and Nakamura M: Unique properties of 189 amino acid isoform of vascular endothelial growth factor in tumorigenesis. Int J Oncol 21: 1251-1257, 2002.
48. Inoue K, Ozeki Y, Suganuma T, Sugiura Y and Tanaka S: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 79: 206-213, 1997.